HyperMed to Present at the BIO CEO and Investor Conference 2006

IMMEDIATE RELEASE

Contact:
Creighton J. Oyler
Vice President, Operations
HyperMed, Inc.
(781) 487-5760
(781) 487-4199 (FAX)
coyler@hypermed-inc.com


HyperMed to Present at the BIO CEO and Investor Conference 2006

HyperMed, Inc., a private medical device company developing medical hyperspectral imaging products initially targeting the diabetic and peripheral disease markets, today announced that the Company will be presenting at the BIO CEO & Investor Conference on Tuesday, February 14th, at the Waldorf-Astoria Hotel in New York City.

Jenny Freeman, HyperMed’s President and CEO, will provide an overview of the Company’s business, technology and upcoming product milestones. The presentation will take place at 10:30 a.m. Eastern.

About HyperMed, Inc.

HyperMed, Inc. is developing and commercializing medical hyperspectral imaging (MHSI) products. The Company has created the first hyperspectral imaging platform for use in medical and surgical applications. HyperMed’s first product, OxyVuTM, initially targets the screening, diagnosis, and monitoring of diabetic foot disease and peripheral arterial disease (PAD). HyperMed’s OxyVu provides previously unavailable information about tissue signatures (spectra) to assist in diagnosis & therapy.

OxyVu will dramatically improve the care and treatment for the millions of individuals with lower extremity complications. In the US alone, over 120,000 people undergo lower extremity amputations each year and millions more will experience pain, impaired mobility, and other related complications as a result of diabetes and PAD. These lower-extremity complications alone, are estimated to cost the medical system over $15 billion per annum.

In addition to the diabetes and PAD markets, HyperMed is also pursuing applications related to wound healing, shock, endoscopy, and intraoperative breast cancer margin detection.

HyperMed has developed a research base through collaboration with major medical centers and United States government agencies. The Company’s technology was recently profiled in clinical journals such as The Lancet and at presentations to the American Diabetes Association, American Heart Association, American Association of Surgical Trauma, and the San Antonio Breast Cancer Symposium.

HyperMed is currently preparing to submit its OxyVu imaging system to the FDA for 510(k) approval. The company expects to receive this approval and have its first units on the market in early 2007.
The company has leveraged founders’ capital and government grant funding to perform clinical research, product development, and intellectual property protection activities. HyperMed is currently in the process of raising private capital to help fund it near-term commercialization efforts.

For more information, contact Creighton Oyler at (781) 487-5760; email: coyler@hypermed-inc.com